VCYT Stock Summary and Trading Ideas (Veracyte | NASDAQ:VCYT)

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Veracyte trades on the NASDAQ stock market under the symbol VCYT.

As of December 17, 2025, VCYT stock price declined to $42.21 with 663,629 million shares trading.

VCYT has a beta of 0.88, meaning it tends to be less sensitive to market movements. VCYT has a correlation of 0.11 to the broad based SPY ETF.

VCYT has a market cap of $3.34 billion. This is considered a Mid Cap stock.

Last quarter Veracyte reported $132 million in Revenue and $.51 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.24.

In the last 3 years, VCYT traded as high as $50.71 and as low as $18.61.

The top ETF exchange traded funds that VCYT belongs to (by Net Assets): IJR, VTI, ARKK, IWM, VB.

VCYT has underperformed the market in the last year with a price return of -2.6% while the SPY ETF gained +11.8%. However, in the short term, VCYT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +30.8% vs +2.0% return in SPY. But in the last 2 weeks, VCYT shares have been beat by the market, returning -8.6% compared to an SPY return of -1.5%.

VCYT support price is $41.67 and resistance is $44.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCYT shares will trade within this expected range on the day.